Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimpinelli, Fulvia, Marchesi, Francesco, Piaggio, Giulia, Giannarelli, Diana, Papa, Elena, Falcucci, Paolo, Spadea, Antonio, Pontone, Martina, Di Martino, Simona, Laquintana, Valentina, La Malfa, Antonia, Di Domenico, Enea Gino, Di Bella, Ornella, Falzone, Gianluca, Ensoli, Fabrizio, Vujovic, Branka, Morrone, Aldo, Ciliberto, Gennaro, Mengarelli, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319901/
https://www.ncbi.nlm.nih.gov/pubmed/34325728
http://dx.doi.org/10.1186/s13045-021-01130-1
Descripción
Sumario:In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.

Ejemplares similares